Epigenetic modulators from "The Big Blue": a treasure to fight against cancer

Cancer Lett. 2014 Sep 1;351(2):182-97. doi: 10.1016/j.canlet.2014.06.005. Epub 2014 Jun 22.

Abstract

Cancer remains a major public health problem in our society. The development of potent novel anti-cancer drugs selective for tumor cells is therefore still required. Deregulation of the epigenetic machinery including DNA methylation, histone modifications and non-coding RNAs is a hallmark of cancer, which provides potential new therapeutic targets. Natural products or their derivatives represent a major class of anti-cancer drugs in the arsenal available to the clinician. However, regarding epigenetically active anti-cancer agents for clinics, the oceans represent a largely untapped resource. This review focuses on marine natural compounds with epigenetic activities and their synthetic derivatives displaying anti-cancer properties including largazole, psammaplins, trichostatins and azumamides.

Keywords: Anti-cancer drugs; DNA methylation; Epigenetic; Histone modifications; Micro-RNAs; Natural marine compounds.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Aquatic Organisms / chemistry
  • Biological Products / chemistry
  • Biological Products / pharmacology
  • DNA Methylation
  • Epigenomics
  • Humans
  • MicroRNAs / genetics
  • Neoplasms / drug therapy*
  • Neoplasms / genetics*

Substances

  • Antineoplastic Agents
  • Biological Products
  • MicroRNAs